Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Vox Sang ; 111(2): 115-9, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27149002

RESUMO

BACKGROUND: In the context of the Official Medicines Control Laboratories plasma pool testing for Parvovirus B19 DNA, we use the cobas TaqScreen DPX test. When we re-evaluated this method using the 3rd B19 DNA WHO IS at the final concentration of 4 log IU/mL, we observed a titre lower than expected, i.e. 3.79 log IU/mL. Therefore, we further investigated the accuracy of the DPX test. MATERIALS & METHODS: The following B19V DNA materials were tested by using both the DPX test and an in-house real-time PCR: The 1st, 2nd and 3rd WHO ISs for B19V DNA The Non WHO B19V DNA Reference Material for NAT The Biological Reference Preparation B19 virus DNA for NAT testing, batch 1 . RESULTS: The DPX test showed a good accuracy for all B19V DNA materials with the exception of the 3rd WHO IS for B19V DNA. In fact, an underestimation of about 38% was observed for all dilutions of this standard with respect to the nominal titre. With the B19V in-house real-time PCR, all four materials proved to be well calibrated against the 1(st) WHO IS for B19V DNA, used as external standard curve. CONCLUSION: In this study, we demonstrated that the DPX test underestimates the B19V DNA content of the 3rd WHO IS for B19V DNA and that this is not due to an incorrect potency assigned to the standard but, most probably, to a mismatch between the primers/probe and the sequence of the target region in the 3rd WHO IS for B19V DNA.


Assuntos
DNA Viral/sangue , Infecções por Parvoviridae/diagnóstico , Parvovirus B19 Humano/genética , Reação em Cadeia da Polimerase em Tempo Real , Sondas de DNA/química , Sondas de DNA/metabolismo , DNA Viral/normas , Humanos , Infecções por Parvoviridae/virologia , Parvovirus B19 Humano/isolamento & purificação , Reação em Cadeia da Polimerase em Tempo Real/métodos , Reação em Cadeia da Polimerase em Tempo Real/normas , Padrões de Referência , Organização Mundial da Saúde
2.
Ital J Neurol Sci ; 9(3): 275-8, 1988 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-3403220

RESUMO

Despite combined treatment (surgery, radio--and chemotherapy) primary central nervous system lymphoma (PCNSL) has generally a poor prognosis. Long surviving cases (more than 5 years) are exceptional. We report a case of a patient completely symptom-free 79 months after craniotomy. Histological diagnosis was diffuse centroblastic-centrocytic malignant lymphoma. Immunohistological study of the lesion was performed. Repeated CT scans reveal no tumor recurrence and screenings for extraneural disease remain negative. The prognostic value of tumor histology is emphasized.


Assuntos
Neoplasias Encefálicas/secundário , Linfoma , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/cirurgia , Terapia Combinada , Quimioterapia Combinada , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA